11/13
03:12 pm
aldx
Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript [Seeking Alpha]
Neutral
Report
Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript [Seeking Alpha]
11/13
07:28 am
aldx
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast [Yahoo! Finance]
Medium
Report
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast [Yahoo! Finance]
11/13
07:00 am
aldx
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
Medium
Report
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
11/11
07:01 am
aldx
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Low
Report
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
11/10
08:03 am
aldx
Aldeyra Therapeutics (NASDAQ:ALDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
Medium
Report
Aldeyra Therapeutics (NASDAQ:ALDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $9.00 price target on the stock.
11/6
07:00 am
aldx
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
Low
Report
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
10/28
07:01 am
aldx
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Medium
Report
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules